Figure 2. FoxP3 intensity in CD4⁺FoxP3⁺ Tregs is reduced in rapidly progressing ALS patients.

1. There was a trend toward reduced numbers of CD4⁺FoxP3⁺ Tregs in the blood of rapidly progressing patients compared with both slowly progressing patients and control volunteers.
2. FoxP3 intensity in CD4⁺FoxP3⁺ Tregs is reduced in rapidly progressing patients compared with slowly progressing patients and compared with control volunteers; slowly progressing patients were not different than controls. ^#p = 0.049 versus slowly progressing ALS patients; **p = 0.015 versus controls.